Impact of Veterinary Vaccines on Human Health and Probable Challenges

Like antibiotics, extensive uncontrolled use of veterinary vaccines might be a threat to human health in occupational livestock production and subsequently in animal food product consumption. Although veterinary vaccines are necessary to control a large variety of infectious diseases in animals, risk assessment, rules, and regulations are highly justified for the sake of human health and safety. Indeed, during the last century, there have been significant changes in livestock production due to the increasing demand for animal products, and these changes have dramatically augmented the occupational exposure of humans to animals. To prevent risks of cross-reactions of veterinary vaccines in humans, strict guidelines are now followed, in every step of vaccine production and people are aware of the consequences. Besides this, systemic biology approaches are also being explored to determine host–pathogen relationships. This mini-review examines some of the scientific bases of this type of risk in the era of systemic medicine, as well as the efficacy or inadequacy of preventive regulations.

PDF

___

Adams, L. G., Khare, S., Lawhon, S. D., Rossetti, C. A., Lewin, H. A., Lipton, M. S., Turse, J. E., Wylie, D. C., Bai, Y., & Drake, K. L. (2011). Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: Linking systems biology with vaccine development. Vaccine, 29(41), 7197–7206. [CrossRef]

Azuaje, F., Zheng, H., Camargo, A., & Wang, H. (2011). Systems-based biological concordance and predictive reproducibility of gene set discovery methods in cardiovascular disease. Journal of Biomedical Informatics, 44(4), 637–647. [CrossRef]

Baurley, J. W., Mcmahan, C. S., Ervin, C. M., Pardamean, B., & Bergen, A. W. (2018). Biosignature discovery for substance use disorders using statistical learning. Trends in Molecular Medicine, 24(2), 221–235. [CrossRef]

Berkelman, R. L. (2003). Human illness associated with use of veterinary vaccines. Clinical Infectious Diseases, 37(3), 407–414. [CrossRef]

Bermejo, A. V., Nielsen, K. N., & Holst, P. J. (2021). Translational oncology comment on: Endogenous retroviruses expressed in human tumours cannot be used as targets for anti-tumour vaccines. Translational Oncology, 14(5), 101040. [CrossRef]

Brauer, R., & Chen, P. (2015). Influenza virus propagation in embryonated chicken eggs. Journal of Visualized Experiments, 97(97), 1–6.[CrossRef]

Bruckner, L. (2010). Viral safety and extraneous agents testing for veterinary vaccines: Rationale for requirements, the European approach. Biologicals, 38(3), 338–339. [CrossRef]

Denner, J. (2021). Endogenous retroviruses expressed in human tumours cannot be used as targets for anti-tumour vaccines. Translational Oncology, 14(1), 100941. [CrossRef]

Dewannieux, M., Ribet, D., & Heidmann, T. (2010). Risks linked to endogenous retroviruses for vaccine production: A general overview. Biologicals, 38(3), 366–370. [CrossRef]

Fisher, B. L. (2014). Human illness associated with use of veterinary vaccine. (Available at: https://www.nvic.org/cmstemplates/nvic/pdf/ live-virus-vaccines-and-vaccine-shedding.pdf)

Francis, M. J. (2017). Vaccination for one health. International Journal of Vaccines and Vaccination, 4(5), 4–6. [CrossRef]

Gombold, J., Karakasidis, S., Niksa, P., Podczasy, J., Neumann, K., Richardson, J., Sane, N., Johnson-Leva, R., Randolph, V., Sadoff, J., Minor, P., Schmidt, A., Duncan, P., & Sheets, R. L. (2014). Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products. Vaccine, 32(24), 2916–2926. [CrossRef]

Hayes, M., Whitesell, M., & Brown, M. A. (2013). Pathological and evolutionary implications of retroviruses as mobile genetic elements. Genes, 4(4), 573–582. [CrossRef]

Ishida, Y., Zhao, K., Greenwood, A. D., & Roca, A. L. (2015). Proliferation of endogenous retroviruses in the early stages of a host germ line invasion. Molecular Biology and Evolution, 32(1), 109–120. [CrossRef]

Kuleš, J., Horvatić, A., Guillemin, N., Galan, A., Mrljak, V., & Bhide, M. (2016). New approaches and omics tools for mining of vaccine candidates against vector-borne diseases. Molecular Biosystems, 12(9), 2680–2694. [CrossRef]

Lee, N. H., Lee, J. A., Park, S. Y., Song, C. S., Choi, I. S., & Lee, J. B. (2012). A review of vaccine development and research for industry animals in Korea. Clinical and Experimental Vaccine Research, 1(1), 18–34. [CrossRef]

Miyazawa, T. (2010). Endogenous retroviruses as potential hazards for vaccines. Biologicals, 38(3), 371–376. [CrossRef]

Parrino, J., & Graham, B. S. (2006). Smallpox vaccines: Past, present, and future. Journal of Allergy and Clinical Immunology, 118(6), 1320–1326. [CrossRef]

Pastoret, P. P. (2010). Human and animal vaccine contaminations. Biologicals, 38(3), 332–334. [CrossRef]

Polak, M. P., Antos, A., Rola, J., & Żmudziński, J. F. (2016). Viral shedders in a herd vaccinated against infection with bovine viral diarrhoea virus (BVDV) without prior testing for the presence of persistently infected animals. Journal of Veterinary Research, 60(4), 379–384. [CrossRef]

Roth, J. A. (2011). Veterinary vaccines and their importance to animal health and public health. Procedia in Vaccinology, 5, 127–136. [CrossRef]

Sheridan, S., & Coughlin, J. (2010). Comparison of requirements in the European Union and United States of America for pre-clinical viral safety testing of veterinary vaccines. Biologicals, 38(3), 340–345. [CrossRef]

Wisher, M. (2002). Biosafety and product release testing issues relevant to replication-competent oncolytic viruses. Cancer Gene Therapy, 9(12), 1056–1061. [CrossRef]